SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
Kate Lynn J. Bill(The Ohio State University Wexner Medical Center), Raphael E. Pollock(The Ohio State University), Chad J. Creighton(Baylor College of Medicine), Bethany C. Prudner(The Ohio State University), Alexander J. Lazar(The University of Texas MD Anderson Cancer Center), Lucia Casadei(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Laurent Debüssche(Sanofi (France)), Abbie Zewdu(The Ohio State University), Dina Lev(Assuta Medical Center), Danielle Braggio(Ono Pharmaceutical (United States)), Isabelle Meaux(Sanofi (France)), Gonzalo Lopez(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Svetlana Bolshakov(The University of Texas MD Anderson Cancer Center), Cédric Barrière(Sanofi (France)), Jeannine Garnett(The University of Texas MD Anderson Cancer Center), Hemant K. Bid(University of Lucknow), XiaoYen Ma(The University of Texas MD Anderson Cancer Center)
Cited by 106
Related Papers
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
|Neoplasia|2017|6.5k
UALCAN: An update to the integrated cancer data analysis platform
|Neoplasia|2022|2.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k